Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 126.96.36.199) - Pipeline Review, H1 2018
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 188.8.131.52) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 184.108.40.206) pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 10, 7, 11 and 3 respectively.
Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Respiratory which include indications Solid Tumor, Metastatic Melanoma, Breast Cancer, Gastric Cancer, Bladder Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Non-Small Cell Lung Cancer, Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastrointestinal Stromal Tumor (GIST), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Bile Duct Cancer (Cholangiocarcinoma), Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Cancer Pain, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Inflammation, Lentigo Maligna Melanoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Ascites, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Osteolysis, Osteosarcoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Uveal Melanoma and Von Hippel-Lindau Syndrome.
The latest report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook